Cannabis plant. Source: ECS Botanics
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ECS Botanics (ECS) secures supply agreement with Australian cannabis company Canngea
  • The one-year rolling agreement is for the supply of medicinal cannabis products and is tipped to bring in revenue of $410,000 per year for ECS
  • The first dispatch of medical cannabis is expected in October and will include dry flowers and oils
  • ECS says the deal validates the growing market in Australia as well as the company’s business model
  • Shares is trading 5.9 per cent higher at 3.6 cents at 12:14pm AEST

ECS Botanics (ECS) has secured a supply agreement with Australian cannabis company Canngea.

ECS is a medicinal cannabis and industrial hemp business with farms and facilities in Tasmania and Victoria for cultivation, processing and manufacturing needs.

Canngea was established in 2017 and focuses on distributing a range of solutions to both international and domestic markets.

The one-year rolling agreement is for the supply of medicinal cannabis products and is tipped to bring in revenue of $410,000 per year for ECS.

The first dispatch of medical cannabis is expected in October and will include dry flowers and oils.

Both parties are able to terminate the agreement following a material breach which can’t be remedied within 20 business days, or either company enters a state of insolvency or liquidation.

ECS said the deal validates the growing market in Australia as well as the company’s business model.

Commenting on the agreement, Canngea’s Managing Director Ryan Ballantyne said working with ECS is key to enhancing local supply capabilities for its existing clients.

“Collaborations like this strengthen the ability of the Australian medicinal
cannabis industry to service growing demand for safe, high-quality, and affordable products.”

ECS is encouraged by market demand for medical cannabis products and said it continues to build a strong sales pipeline with the aim of significantly increasing the scale of cannabis production.

Additionally, the company said other contracts are in the final stages and it will update the market accordingly.

Shares were trading 5.9 per cent higher at 3.6 cents at 12:14pm AEST.

ECS by the numbers
More From The Market Online
Rejection concept

Mayne Pharma plummets -30% as foreign review board rejects Cosette buyout

Mayne Pharma has revealed a letter from Chalmers has outlined that the gov't (via the FIRB)…
Blood plasma in a bag

CSL tumbles -15% as it points to reduced vaccination rates in US; lower Chinese demand

CSL Limited has tumbled nearly -15% in Tuesday trades after the market balked at its latest…
CSL Limited logo

CSL price walloped -10% on widespread ‘cost-saving’ job cuts, Seqirus spinoff plans

Earnings day hasn’t quite been a shining one for CSL Ltd (ASX:CSL), with the $117 billion biotechnology bluechip unveiling
Lung imaging concept

4DMedical climbing back towards $2/sh on back of Stanford lung imaging tech rollout

4DX Medical has popped once again on Wednesday after demonstrating its next-generation lung imaging tech at…